CompletedNCT00249236

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolarity type I

Medication studyAges 18+

The study in practice

Understand this study

This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.

Study clarity

Study start dateMarch 2001

Recruitment status: Completed
Enrollment listed in the registry: 291
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Not clearly listed
Age range: Over 18 Years
Official registry ID: NCT00249236
Official title: Show the full official title
The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Risperidone, oral tablets.

Who was this study for?

This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.